In a recent announcement, 23andMe Holding Co. (NASDAQ:ME) has disclosed that the U.S. Food and Drug Administration (FDA) has given the green light to its investigational new drug application for 23ME-01473 (‘1473), a natural killer (NK) cell activator designed to combat cancer.
What Happened: As per the company’s press release, ‘1473 is set to be evaluated in a Phase 1 clinical study commencing in the first half of 2024. The study will focus on participants with advanced solid tumors.
The drug targets ULBP6, a protein found on the surface of cancer cells, and aims to restore the immune system’s ability to recognize and destroy these cells. ‘1473 is also Fc-effector enhanced, providing another method for NK cells to induce cell death of ULBP6-expressing cancer cells.
See Also: Eli Lilly Wants to Expand Access to Weight-Loss Treatments In Germany, In Talks With Government
Furthermore, the drug has the potential to ...